Romeo Paola, D'Anna Rosario, Corrado Francesco
Obstetrics and Gynecology Unit, Department of Human Pathology, University of Messina (Italy), Via Consolare Valeria, 1, 98125 Messina, Italy.
J Clin Med. 2024 Sep 12;13(18):5387. doi: 10.3390/jcm13185387.
Our hypothesis is that myoinositol and metformin in pregnant women with high-risk factors for glucose intolerance would reduce insulin resistance and consequently lower the incidence of gestational diabetes mellitus (GDM), a metabolic disorder of pregnancy characterized by maternal hyperglycemia due to deficient response to physiological insulin resistance, which may have a negative impact on perinatal outcome and long-term sequelae. In recent years, this pathology has become increasingly important given the global obesity epidemic and the delay in becoming pregnant, especially in industrialized countries. For this reason, the attempt to prevent, rather than cure, gestational diabetes is particularly important. In addition to lifestyle changes (especially diet and doing more exercise), myoinositol and metformin are the most promising factors at the moment, although not all RCTs published so far agree on their real effectiveness. A review of the articles published so far allows us to assume, albeit with some distinctions, that they can play a positive role.
我们的假设是,对于有糖耐量异常高危因素的孕妇,肌醇和二甲双胍可降低胰岛素抵抗,从而降低妊娠期糖尿病(GDM)的发病率。妊娠期糖尿病是一种妊娠代谢紊乱疾病,其特征是由于对生理性胰岛素抵抗反应不足导致母体高血糖,这可能对围产期结局和远期后遗症产生负面影响。近年来,鉴于全球肥胖流行以及怀孕年龄推迟,尤其是在工业化国家,这种疾病变得越来越重要。因此,尝试预防而非治疗妊娠期糖尿病尤为重要。除了生活方式改变(特别是饮食和增加运动)外,肌醇和二甲双胍是目前最有前景的因素,尽管迄今为止发表的并非所有随机对照试验都认同它们的实际效果。对迄今为止发表的文章进行综述后,我们可以认为,尽管存在一些差异,但它们可以发挥积极作用。